Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 17,717 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $18.94, for a total value of $335,559.98. Following the sale, the chief financial officer owned 122,851 shares in the company, valued at $2,326,797.94. The trade was a 12.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, July 28th, Thomas Catinazzo sold 1,459 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.61, for a total transaction of $27,151.99.
• On Monday, July 6th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.69, for a total transaction of $331,130.73.
• On Monday, June 22nd, Thomas Catinazzo sold 187,163 shares of Relay Therapeutics stock. The stock was sold at an average price of $16.97, for a total transaction of $3,176,156.11.

Relay Therapeutics Stock Performance

Shares of RLAY stock opened at $18.66 on Thursday. The firm has a market cap of $4.09 billion, a price-to-earnings ratio of -11.89 and a beta of 1.69. Relay Therapeutics, Inc. has a 52 week low of $3.87 and a 52 week high of $21.27. The firm’s 50-day simple moving average is $19.37 and its two-hundred day simple moving average is $15.34.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The business had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.96 million. Analysts forecast that Relay Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Hedge Funds Weigh In On Relay Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RLAY. AQR Capital Management LLC boosted its position in shares of Relay Therapeutics by 11.9% during the 1st quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock valued at $956,000 after acquiring an additional 38,812 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Relay Therapeutics by 6.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock worth $221,000 after acquiring an additional 5,238 shares in the last quarter. Millennium Management LLC grew its position in Relay Therapeutics by 14.6% in the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after acquiring an additional 374,491 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Relay Therapeutics during the 1st quarter valued at about $53,000. Finally, Woodline Partners LP grew its position in Relay Therapeutics by 448.4% during the first quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock valued at $3,979,000 after acquiring an additional 1,241,657 shares during the last quarter. 96.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on RLAY. Barclays increased their price objective on Relay Therapeutics from $27.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Guggenheim reaffirmed a “buy” rating on shares of Relay Therapeutics in a research report on Friday, August 7th. JPMorgan Chase & Co. lifted their price objective on Relay Therapeutics from $28.00 to $31.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Canaccord Genuity Group assumed coverage on Relay Therapeutics in a research note on Thursday, July 16th. They issued a “buy” rating and a $29.00 price objective on the stock. Finally, UBS Group set a $26.00 price objective on shares of Relay Therapeutics in a report on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $25.92.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.